Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: Cancer. 2021 Nov 2;127(24):4546–4556. doi: 10.1002/cncr.33992

Figure 4.

Figure 4.

Schematic diagram summarizing significant relationships between bevacizumab exposure, the AE trajectory group, clinical outcomes, and patient-reported outcomes. The thickest arrow indicates P < .001, medium arrows indicate P < .01, and thin arrows indicate P < .05. For Cardiac Traj group → physical well-being domain, P = .054. AE indicates adverse event; Cardiac, Cardiac Traj group; Neuro, Neuro Traj group; Mixed Reactions, Mixed Reactions Traj group, Low AE, Low AE Traj group.